Long-term capital, deployed by a highly experienced team, enabling a new generation of companies to grow
/ / /
Gurnet Point Capital is a unique healthcare fund founded by Ernesto Bertarelli and led by Christopher A. Viehbacher. Together, as both executives and investors, they have many years of expertise in an industry for which they share a passion.
As Managing Partner, Chris has brought together a team of experienced professionals to invest long-term capital and to support entrepreneurs in building a new generation of companies. Based in Cambridge, Massachusetts, and with an office in San Francisco, Gurnet Point Capital has an initial capital allocation of $2 billion. Its remit in healthcare is global, encompassing life sciences and medical technologies.
In Ernesto Bertarelli and Waypoint Capital, Gurnet Point has a partner that is similarly committed on a long-term bigger picture. This allows it to forge synergies across its portfolio of investments, which means that it can draw upon considerable know-how in clinical trial design and execution, value-driven drug development, regulatory affairs, toxicology and other areas related to bringing early-stage medicines and devices to patients.
The fund invests across all stages of product development through to commercialisation and does so with an approach that is a hybrid of venture and private equity investing strategies. It is governed by a guiding tenet that even the earliest of technologies must present a clear commercial case, benefiting both patients and the healthcare system as a whole.
Consistent with the amount of capital, time and energy that it dedicates, Gurnet Point Capital will generally seek to be, over time, the majority – or at least principal - investor in each of its companies.